, AIDS by the numbers. AIDS_by_the_Numbers_2015_en.pdf, 2015.

, Annual Report, 2015.

L. Ferradini, D. Laureillard, N. Prak, C. Ngeth, M. Fernandez et al., Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia, AIDS, vol.21, pp.2293-301, 2007.

Y. Madec, D. Laureillard, L. Pinoges, M. Fernandez, N. Prak et al., Response to highly active antiretroviral therapy among severely immunocompromised HIV-infected patients in Cambodia, AIDS, vol.21, pp.351-360, 2007.

O. Ségéral, S. Limsreng, J. Nouhin, C. Hak, S. Ngin et al., Short communication: three years follow-up of first-line antiretroviral therapy in Cambodia: negative impact of prior antiretroviral treatment, AIDS Res Hum Retroviruses, vol.27, pp.597-603, 2011.

P. Isaakidis, M. Raguenaud, V. Te, C. S. Tray, K. Akao et al., High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia, J Int AIDS Soc, vol.13, p.11, 2010.

O. Segeral, Y. Madec, B. Ban, V. Ouk, C. R. Hak et al., Simplified assessment of antiretroviral adherence and prediction of virological efficacy in HIV-infected patients in Cambodia, AIDS Res Treat, p.142076, 2010.

B. Spire, P. Carrieri, P. Sopha, C. Protopopescu, N. Prak et al., Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment, Antivir Ther, vol.13, pp.697-703, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00320461

L. Ferradini, V. Ouk, O. Segeral, J. Nouhin, A. Dulioust et al., High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. J Int AIDS Soc, 2011.
URL : https://hal.archives-ouvertes.fr/pasteur-00598973

M. Pujades-rodríguez, S. Balkan, L. Arnould, M. Brinkhof, and A. Calmy, AIDS Working Group of MSF. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries, JAMA, vol.304, pp.303-315, 2010.

V. P. Thao, V. M. Quang, M. Wolbers, N. D. Anh, C. Shikuma et al., Secondline HIV therapy outcomes and determinants of mortality at the largest HIV referral center in Southern Vietnam, Medicine, vol.94, 2015.

D. C. Boettiger, V. K. Nguyen, N. Durier, H. V. Bui, H. Sim et al., Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational database, J Acquir Immune Defic Syndr, vol.68, pp.186-95, 2015.

, Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach, 2013.

P. Carrieri, V. Cailleton, L. Moing, V. Spire, B. Dellamonica et al., The dynamic of adherence to highly active antiretroviral therapy: results from the French national APROCO cohort, J Acquir Immune Defic Syndr, vol.28, pp.232-241, 2001.

M. M. Win, W. Maek-a-nantawat, B. Phonrat, S. Kiertiburanakul, and S. Sungkanuparph, Virologic and immunologic outcomes of the second-line regimens of antiretroviral therapy among HIV-infected PATIENTS in Thailand, J Int Assoc Physicians AIDS Care (Chic), vol.10, pp.57-63, 2011.

O. Ajose, S. Mookerjee, E. J. Mills, A. Boulle, and N. Ford, Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis, AIDS, vol.26, pp.929-967, 2012.

D. Collier, C. Iwuji, A. Derache, T. De-oliveira, N. Okesola et al., Virological outcomes of second-line protease inhibitor-based treatment for human immunodeficiency virus type 1 in a high-prevalence rural South African setting: a competing-risks prospective cohort analysis, Clin Infect Dis, vol.64, pp.1006-1022, 2017.

J. Chakravarty, S. Sundar, A. Chourasia, P. N. Singh, S. Kurle et al., Outcome of patients on second line antiretroviral therapy under programmatic condition in India, BMC Infect Dis, vol.15, p.517, 2015.

M. P. Fox, R. Berhanu, K. Steegen, C. Firnhaber, P. Ive et al., Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in, Trop Med Int Health, vol.21, issue.9, pp.1131-1138, 2016.

L. Sagaon-teyssier, M. Mrenda, B. Khol, V. Ferradini, L. Mam et al., Adherence to PI-based 2nd-line regimens in Cambodia is not simply a question of individual behaviour: the ANRS 12276 2PICAM study, Trop Med Int Health, vol.22, issue.11, pp.1428-1463, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01985861

F. Raffi, Y. Yazdanpanah, F. Fagnani, C. Laurendeau, A. Lafuma et al., Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French national healthcare insurance database, J Antimicrob Chemother, vol.70, pp.2121-2129, 2015.

J. Molina, J. Andrade-villanueva, J. Echevarria, P. Chetchotisakd, J. Corral et al., Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study, J Acquir Immune Defic Syndr, vol.53, pp.323-355, 2010.

M. J. Kim, S. Kim, H. Chang, Y. Kim, J. S. Jung et al., Comparison of antiretroviral regimens: adverse effects and tolerability failure that cause regimen switching, vol.47, pp.231-239, 2015.

H. E. Rawizza, B. Chaplin, S. T. Meloni, K. M. Darin, O. Olaitan et al., Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria, PLoS One, vol.8, 2013.

V. P. Thao, V. M. Quang, J. N. Day, N. T. Chinh, C. M. Shikuma et al., High prevalence of PI resistance in patients failing second-line ART in Vietnam, J Antimicrob Chemother, vol.71, pp.762-74, 2016.

T. S. Boender, R. L. Hamers, P. Ondoa, M. Wellington, C. Chimbetete et al., Protease inhibitor resistance in the first 3 years of second-line antiretroviral therapy for HIV-1 in Sub-Saharan Africa, J Infect Dis, vol.214, issue.6, pp.873-83, 2016.

, Geneva: World Health Organization, 2017.

S. Rhee, M. R. Jordan, E. Raizes, A. Chua, N. Parkin et al., HIV-1 drug resistance mutations: potential applications for point-of-care genotypic resistance testing, PLoS One, vol.10, 2015.

L. Rosa, A. M. Harrison, L. J. Taiwo, B. Wallis, C. L. Zheng et al., Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study, Lancet HIV, vol.3, issue.16, p.30011, 2016.

J. Amin, M. A. Boyd, N. Kumarasamy, C. L. Moore, M. H. Losso et al., Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection, PLoS One, vol.10, 2015.

S. Lambert-niclot, E. C. George, A. Pozniak, E. White, C. Schwimmer et al., Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART, J Antimicrob Chemother, vol.71, pp.1056-62, 2016.

C. Gubavu, T. Prazuck, M. Niang, J. Buret, C. Mille et al., Dolutegravirbased monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients, J Antimicrob Chemother, vol.71, 2016.